{
    "clinicalTrialHighDropout": {
        "id": "1",
        "messages": [
            {
                "content": "Which indications have the highest clinical trial dropout rates?",
                "id": "1",
                "sender": "You",
                "timestamp": "Wednesday 9:20am"
            },
            {
                "content": "The following indications have the highest clinical trial dropout rates:\n* [ph1-positive chronic myelogenous leukemia](http://localhost:3000/core/dashboard?endYear=2024&startYear=2014&terms=ph1-positive%20cml) (58%)\n* [small cell carcinoma of the lung](http://localhost:3000/core/dashboard?endYear=2024startYear=2014&terms=sccl) (53%)\n* [hematologic cancers](http://localhost:3000/core/dashboard?endYear=2024&startYear=2014&terms=hematologic%20neoplasms) (53%)\n* [non-small cell lung carcinoma](http://localhost:3000/core/dashboard?endYear=2024&startYear=2014&terms=non-small%20cell%20lung%20carcinoma) (52%)\n* [melanoma](http://localhost:3000/core/dashboard?endYear=2024&startYear=2014&terms=melanoma) (51%)\n ",
                "id": "2",
                "sender": {
                    "name": "Biosym Bot",
                    "username": "@biosymbolics"
                },
                "timestamp": "Wednesday 9:21am"
            },
            {
                "content": "What are non-cancer indications with the highest clinical trial dropout rates?",
                "id": "3",
                "sender": "You",
                "timestamp": "Wednesday 9:23am"
            },
            {
                "content": "The following non-cancer indications have the highest clinical trial dropout rates:\n* [alzheimer's disease](http://localhost:3000/core/dashboard?endYear=2024&startYear=2014&terms=alzheimer's%20disease) (50%)\n* [contraceptive methods](http://localhost:3000/core/dashboard?endYear=2024startYear=2014&terms=contraceptive%20methods) (53%)\n* [schizophrenia](http://localhost:3000/core/dashboard?endYear=2024&startYear=2014&terms=schizophrenia) (43%)\n* [crohn disease](http://localhost:3000/core/dashboard?endYear=2024&startYear=2014&terms=crohn%20disease) (52%)\n* [idiopathic pulmonary arterial hypertension](http://localhost:3000/core/dashboard?endYear=2024&startYear=2014&terms=idiopathic%20pulmonary%20arterial%20hypertension) (51%)\n ",
                "id": "4",
                "sender": {
                    "name": "Biosym Bot",
                    "username": "@biosymbolics"
                },
                "timestamp": "Wednesday 9:24am"
            },
            {
                "content": "In idiopathic pulmonary arterial hypertension, show me a chart of investigational drugs by top dropout reasons.",
                "id": "5",
                "sender": "You",
                "timestamp": "Wednesday 9:25am"
            },
            {
                "content": "[{\"intervention\" : \"enzyme inhibitors\", \"reason\" : \"Death\", \"count\" : 66},\n {\"intervention\" : \"vasodilator agents\", \"reason\" : \"Withdrawal by Subject\", \"count\" : 57},\n {\"intervention\" : \"vasodilator agents\", \"reason\" : \"Death\", \"count\" : 56},\n {\"intervention\" : \"antihypertensive agents\", \"reason\" : \"Withdrawal by Subject\", \"count\" : 56},\n {\"intervention\" : \"enzyme inhibitors\", \"reason\" : \"Withdrawal by Subject\", \"count\" : 53},\n {\"intervention\" : \"urological agents\", \"reason\" : \"Withdrawal by Subject\", \"count\" : 47},\n {\"intervention\" : \"phosphodiesterase inhibitors\", \"reason\" : \"Withdrawal by Subject\", \"count\" : 47},\n {\"intervention\" : \"antihypertensive agents\", \"reason\" : \"Death\", \"count\" : 43},\n {\"intervention\" : \"urological agents\", \"reason\" : \"Death\", \"count\" : 41},\n {\"intervention\" : \"phosphodiesterase inhibitors\", \"reason\" : \"Death\", \"count\" : 41},\n {\"intervention\" : \"enzyme inhibitors\", \"reason\" : \"Protocol Violation\", \"count\" : 41},\n {\"intervention\" : \"endothelin receptor antagonists\", \"reason\" : \"Death\", \"count\" : 40},\n {\"intervention\" : \"vasodilator agents\", \"reason\" : \"Lost to Follow-up\", \"count\" : 39},\n {\"intervention\" : \"endothelin receptor antagonists\", \"reason\" : \"Withdrawal by Subject\", \"count\" : 38},\n {\"intervention\" : \"endothelin receptor antagonists\", \"reason\" : \"Investigator\", \"count\" : 22},\n {\"intervention\" : \"endothelin receptor antagonists\", \"reason\" : \"Lack of Efficacy\", \"count\" : 22},\n {\"intervention\" : \"sildenafil citrate\", \"reason\" : \"Withdrawal by Subject\", \"count\" : 38},\n {\"intervention\" : \"sildenafil citrate\", \"reason\" : \"Death\", \"count\" : 36},\n {\"intervention\" : \"phosphodiesterase inhibitors\", \"reason\" : \"Protocol Violation\", \"count\" : 32},\n {\"intervention\" : \"vasodilator agents\", \"reason\" : \"Protocol Violation\", \"count\" : 32},\n {\"intervention\" : \"urological agents\", \"reason\" : \"Protocol Violation\", \"count\" : 32},\n {\"intervention\" : \"antihypertensive agents\", \"reason\" : \"Lost to Follow-up\", \"count\" : 32},\n {\"intervention\" : \"enzyme inhibitors\", \"reason\" : \"Lost to Follow-up\", \"count\" : 32},\n {\"intervention\" : \"phosphodiesterase inhibitors\", \"reason\" : \"Lost to Follow-up\", \"count\" : 30},\n {\"intervention\" : \"urological agents\", \"reason\" : \"Lost to Follow-up\", \"count\" : 30},\n {\"intervention\" : \"sildenafil citrate\", \"reason\" : \"Protocol Violation\", \"count\" : 29},\n {\"intervention\" : \"antihypertensive agents\", \"reason\" : \"Investigator\", \"count\" : 26},\n {\"intervention\" : \"vasodilator agents\", \"reason\" : \"Investigator\", \"count\" : 25},\n {\"intervention\" : \"sildenafil citrate\", \"reason\" : \"Lost to Follow-up\", \"count\" : 25},\n {\"intervention\" : \"protein kinase inhibitors\", \"reason\" : \"Death\", \"count\" : 25},\n {\"intervention\" : \"bosentan\", \"reason\" : \"Withdrawal by Subject\", \"count\" : 24},\n {\"intervention\" : \"endothelin receptor antagonists\", \"reason\" : \"Lost to Follow-up\", \"count\" : 22},\n {\"intervention\" : \"antihypertensive agents\", \"reason\" : \"Protocol Violation\", \"count\" : 20},\n {\"intervention\" : \"platelet aggregation inhibitors\", \"reason\" : \"Withdrawal by Subject\", \"count\" : 20},\n {\"intervention\" : \"platelet aggregation inhibitors\", \"reason\" : \"Death\", \"count\" : 20},\n {\"intervention\" : \"bosentan\", \"reason\" : \"Death\", \"count\" : 19},\n {\"intervention\" : \"urological agents\", \"reason\" : \"Investigator\", \"count\" : 18},\n {\"intervention\" : \"enzyme inhibitors\", \"reason\" : \"Lack of Efficacy\", \"count\" : 18},\n {\"intervention\" : \"phosphodiesterase inhibitors\", \"reason\" : \"Investigator\", \"count\" : 18},\n {\"intervention\" : \"enzyme inhibitors\", \"reason\" : \"Investigator\", \"count\" : 18},\n {\"intervention\" : \"vasodilator agents\", \"reason\" : \"Lack of Efficacy\", \"count\" : 17},\n {\"intervention\" : \"citric acid\", \"reason\" : \"Protocol Violation\", \"count\" : 17},\n {\"intervention\" : \"citric acid\", \"reason\" : \"Lost to Follow-up\", \"count\" : 17},\n {\"intervention\" : \"anticoagulants\", \"reason\" : \"Protocol Violation\", \"count\" : 17},\n {\"intervention\" : \"anticoagulants\", \"reason\" : \"Lost to Follow-up\", \"count\" : 17},\n {\"intervention\" : \"sequestering agents\", \"reason\" : \"Protocol Violation\", \"count\" : 17},\n {\"intervention\" : \"chelating agents\", \"reason\" : \"Lost to Follow-up\", \"count\" : 17},\n {\"intervention\" : \"sequestering agents\", \"reason\" : \"Lost to Follow-up\", \"count\" : 17},\n {\"intervention\" : \"chelating agents\", \"reason\" : \"Protocol Violation\", \"count\" : 17},\n {\"intervention\" : \"tadalafil\", \"reason\" : \"Investigator\", \"count\" : 17},\n {\"intervention\" : \"platelet aggregation inhibitors\", \"reason\" : \"Lost to Follow-up\", \"count\" : 16},\n {\"intervention\" : \"tadalafil\", \"reason\" : \"Withdrawal by Subject\", \"count\" : 16},\n {\"intervention\" : \"enzyme inhibitors\", \"reason\" : \"Investigator\", \"count\" : 14},\n {\"intervention\" : \"phosphodiesterase inhibitors\", \"reason\" : \"Lack of Efficacy\", \"count\" : 14},\n {\"intervention\" : \"sequestering agents\", \"reason\" : \"Withdrawal by Subject\", \"count\" : 14},\n {\"intervention\" : \"chelating agents\", \"reason\" : \"Withdrawal by Subject\", \"count\" : 14},\n {\"intervention\" : \"sildenafil citrate\", \"reason\" : \"Lack of Efficacy\", \"count\" : 14},\n {\"intervention\" : \"iloprost\", \"reason\" : \"Lost to Follow-up\", \"count\" : 14},\n {\"intervention\" : \"macitentan\", \"reason\" : \"Death\", \"count\" : 14},\n {\"intervention\" : \"urological agents\", \"reason\" : \"Lack of Efficacy\", \"count\" : 14},\n {\"intervention\" : \"iloprost\", \"reason\" : \"Withdrawal by Subject\", \"count\" : 14},\n {\"intervention\" : \"anticoagulants\", \"reason\" : \"Withdrawal by Subject\", \"count\" : 14},\n {\"intervention\" : \"protein kinase inhibitors\", \"reason\" : \"Investigator\", \"count\" : 14},\n {\"intervention\" : \"citric acid\", \"reason\" : \"Withdrawal by Subject\", \"count\" : 14},\n {\"intervention\" : \"citric acid\", \"reason\" : \"Death\", \"count\" : 13},\n {\"intervention\" : \"chelating agents\", \"reason\" : \"Death\", \"count\" : 13},\n {\"intervention\" : \"anticoagulants\", \"reason\" : \"Death\", \"count\" : 13},\n {\"intervention\" : \"iloprost\", \"reason\" : \"Death\", \"count\" : 13},\n {\"intervention\" : \"antihypertensive agents\", \"reason\" : \"Disease progression\", \"count\" : 13},\n {\"intervention\" : \"sequestering agents\", \"reason\" : \"Death\", \"count\" : 13},\n {\"intervention\" : \"treprostinil\", \"reason\" : \"Death\", \"count\" : 12},\n {\"intervention\" : \"endothelin receptor antagonists\", \"reason\" : \"Disease progression\", \"count\" : 12},\n {\"intervention\" : \"bosentan\", \"reason\" : \"Disease progression\", \"count\" : 12},\n {\"intervention\" : \"tadalafil\", \"reason\" : \"Death\", \"count\" : 12},\n {\"intervention\" : \"riociguat\", \"reason\" : \"Death\", \"count\" : 12},\n {\"intervention\" : \"riociguat\", \"reason\" : \"Withdrawal by Subject\", \"count\" : 12},\n {\"intervention\" : \"vasodilator agents\", \"reason\" : \"Investigator\", \"count\" : 11},\n {\"intervention\" : \"imatinib mesylate\", \"reason\" : \"Death\", \"count\" : 11},\n {\"intervention\" : \"platelet aggregation inhibitors\", \"reason\" : \"Investigator\", \"count\" : 11},\n {\"intervention\" : \"iloprost\", \"reason\" : \"Investigator\", \"count\" : 11},\n {\"intervention\" : \"treprostinil\", \"reason\" : \"Withdrawal by Subject\", \"count\" : 11},\n {\"intervention\" : \"macitentan\", \"reason\" : \"Lost to Follow-up\", \"count\" : 11},\n {\"intervention\" : \"citric acid\", \"reason\" : \"Lack of Efficacy\", \"count\" : 10},\n {\"intervention\" : \"platelet aggregation inhibitors\", \"reason\" : \"Disease progression\", \"count\" : 10},\n {\"intervention\" : \"phosphodiesterase inhibitors\", \"reason\" : \"Disease progression\", \"count\" : 10},\n {\"intervention\" : \"sildenafil citrate\", \"reason\" : \"Disease progression\", \"count\" : 10},\n {\"intervention\" : \"protein kinase inhibitors\", \"reason\" : \"Protocol Violation\", \"count\" : 10},\n {\"intervention\" : \"antihypertensive agents\", \"reason\" : \"Investigator\", \"count\" : 10},\n {\"intervention\" : \"sequestering agents\", \"reason\" : \"Lack of Efficacy\", \"count\" : 10},\n {\"intervention\" : \"vasodilator agents\", \"reason\" : \"Disease progression\", \"count\" : 10},\n {\"intervention\" : \"chelating agents\", \"reason\" : \"Lack of Efficacy\", \"count\" : 10}]",
                "id": "6",
                "sender": {
                    "name": "Biosym Bot",
                    "username": "@biosymbolics"
                },
                "timestamp": "Wednesday 9:25am",
                "type": "HEATMAP"
            },
            {
                "content": "What are typical clinical development timelines in PAH?",
                "id": "7",
                "sender": "You",
                "timestamp": "Wednesday 9:30am"
            },
            {
                "content": "\n [\n {\n \"stage\": \"Phase 1\",\n \"offset\": 0,\n \"median_duration\": 1.5,\n \"iqr\": 0.5\n },\n {\n \"stage\": \"Phase 2\",\n \"offset\": 1.5,\n \"median_duration\": 2,\n \"iqr\": 0.7\n },\n {\n \"stage\": \"Phase 3\",\n \"offset\": 3.5,\n \"median_duration\": 3,\n \"iqr\": 1\n },\n {\n \"stage\": \"FDA Review\",\n \"offset\": 6.5,\n \"median_duration\": 1.5,\n \"iqr\": 0.5\n }\n ]\n ",
                "description": "Here are typical clinical development timelines in PAH, in years:",
                "id": "8",
                "sender": {
                    "name": "Biosym Bot",
                    "username": "@biosymbolics"
                },
                "timestamp": "Wednesday 9:30am",
                "type": "TIMELINE"
            },
            {
                "content": "Is there a correlation between dropout rates and trial duration?",
                "id": "9",
                "sender": "You",
                "timestamp": "Wednesday 9:31am"
            }
        ],
        "sender": {
            "name": "Biosym Bot",
            "username": "@biosymbolics"
        }
    },
    "drugDeliverySystems": {
        "id": "1",
        "messages": [
            {
                "content": "What are characteristics of drugs that would have greater efficacy if they could cross the blood brain barrier?",
                "id": "1",
                "sender": "You",
                "timestamp": "Wednesday 9:20am"
            },
            {
                "content": "Here are some key characteristics that would make a drug more likely to have improved efficacy if its ability to cross the blood-brain barrier (BBB) was enhanced:\n* Targets the central nervous system - The drug's intended mechanism of action or therapeutic target is located in the brain or spinal cord. For example, drugs treating Alzheimer's, Parkinson's, psychiatric disorders, chronic pain, etc.\n* Hydrophilic - Highly lipophilic (fat-soluble) small molecules can sometimes passively diffuse across the BBB. Hydrophilic compounds have a harder time crossing. Making hydrophilic drugs more hydrophobic can improve permeation.\n* Large molecular weight - Small molecules under 500 Da can more easily cross the BBB compared to larger compounds like peptides or antibodies. Strategies like nanoparticle encapsulation can help transport large molecules.\n* Substrate for efflux pumps - Transporters like p-glycoprotein at the BBB actively pump many drugs back into the bloodstream. Inhibiting these pumps could give more brain exposure.\n* Positive charge - The BBB favors passive diffusion of neutral or negatively charged molecules. Adding negative charge via salts or esters can sometimes improve penetration.\n* Brain-specific delivery - Having a targeting mechanism for enhanced brain vs peripheral uptake helps minimize side effects and maximize CNS action.\n\nThe ideal candidate is a hydrophilic, high molecular weight CNS-active compound that is subject to extensive efflux. Overcoming these barriers to improve brain penetration would significantly enhance its efficacy.\n ",
                "id": "2",
                "sender": {
                    "name": "Biosym Bot",
                    "username": "@biosymbolics"
                },
                "timestamp": "Wednesday 9:21am"
            },
            {
                "content": "What are compounds that failed clinical trials for indications in CNS, with off-target effects in the periphery?",
                "id": "3",
                "sender": "You",
                "timestamp": "Wednesday 9:22am"
            },
            {
                "content": "<<< answer >>>",
                "id": "4",
                "sender": {
                    "name": "Biosym Bot",
                    "username": "@biosymbolics"
                },
                "timestamp": "Wednesday 9:23am"
            }
        ],
        "sender": {
            "name": "Biosym Bot",
            "username": "@biosymbolics"
        }
    },
    "findExceptionalCompanies": {
        "id": "1",
        "messages": [
            {
                "content": "What are promising seed-stage biotechs, innovating in drug delivery systems?",
                "id": "1",
                "sender": "You",
                "timestamp": "Wednesday 9:00am"
            },
            {
                "content": "...",
                "id": "2",
                "sender": {
                    "name": "Biosym Bot",
                    "username": "@biosymbolics"
                },
                "timestamp": "Wednesday 11:30am"
            }
        ],
        "sender": {
            "name": "Biosym Bot",
            "username": "@biosymbolics"
        }
    },
    "tradingBelowCash": {
        "id": "1",
        "messages": [
            {
                "content": "What biopharma companies are trading below cash value?",
                "id": "1",
                "sender": "You",
                "timestamp": "Wednesday 9:00am"
            },
            {
                "content": "Here are some biopharma companies that are trading below cash value: \n\n* Amneal Pharmaceuticals, Inc. ([AMRX](https://finance.yahoo.com/quote/AMRX)) (62%)\n\n* Grifols, S.A. ([GRFS](https://finance.yahoo.com/quote/GRFS)) (78%)\n\n* Embecta Corporation ([EMBI](https://finance.yahoo.com/quote/EMBI)) (78%)\n\n* Coherus BioSciences, Inc. ([CHRS](https://finance.yahoo.com/quote/CHRS)) (64%)\n\n* 2seventy bio, Inc. ([TSVT](https://finance.yahoo.com/quote/TSVT)) (82%)\n\n* Viatris Inc. ([VTRS](https://finance.yahoo.com/quote/VTRS)) (79%)\n\n[See 43 more](http://localhost:3000/core/dashboard?endYear=2024&queryType=OR&startYear=2014&terms=grifols)\n ",
                "id": "2",
                "sender": {
                    "name": "Biosym Bot",
                    "username": "@biosymbolics"
                },
                "timestamp": "Wednesday 11:30am"
            },
            {
                "content": "What drug entities are owned by those companies?",
                "id": "3",
                "sender": "You",
                "timestamp": "Wednesday 2:00pm"
            },
            {
                "content": "Some entities include:\n* [alpha1-proteinase inhibitor](http://localhost:3000/core/dashboard?endYear=2024&queryType=OR&startYear=2014&terms=alpha1-proteinase%20inhibitor)\n\n* [alfa ανβ3 integrin antagonist](http://localhost:3000/core/dashboard?endYear=2024&queryType=OR&startYear=2014&terms=ανβ3%20integrin)\n\n* [il6 inhibitor](http://localhost:3000/core/dashboard?endYear=2024&queryType=OR&startYear=2014&terms=il6%20inhibitor)\n\n* [anti-d-dimer recombinant antibodies](http://localhost:3000/core/dashboard?endYear=2024&queryType=OR&startYear=2014&terms=anti-d-dimer%20antibody)\n\n[View all 250 entities](http://localhost:3000/core/dashboard?endYear=2024&queryType=OR&startYear=2014&terms=grifols)",
                "id": "4",
                "sender": {
                    "name": "Biosym Bot",
                    "username": "@biosymbolics"
                },
                "timestamp": "Wednesday 4:30pm"
            },
            {
                "content": "Which of those drugs are first-in-class or a novel mechanism of action?",
                "id": "5",
                "sender": "You",
                "timestamp": "Wednesday 2:01pm"
            },
            {
                "content": "10 of those entities are first-in-class or a novel mechanism of action:\n* [alpha1-proteinase inhibitor](http://localhost:3000/core/dashboard?endYear=2024&queryType=OR&startYear=2014&terms=alpha1-proteinase%20inhibitor)\n\n* [ανβ3 integrin antagonist](http://localhost:3000/core/dashboard?endYear=2024&queryType=OR&startYear=2014&terms=ανβ3%20integrin)\n\n* [il6 inhibitor](http://localhost:3000/core/dashboard?endYear=2024&queryType=OR&startYear=2014&terms=il6%20inhibitor)\n\n* [anti-d-dimer recombinant antibodies](http://localhost:3000/core/dashboard?endYear=2024&queryType=OR&startYear=2014&terms=anti-d-dimer%20antibody)\n",
                "id": "6",
                "sender": {
                    "name": "Biosym Bot",
                    "username": "@biosymbolics"
                },
                "timestamp": "Wednesday 2:02pm"
            },
            {
                "content": "What are the primary indications for ανβ3 integrin antagonists?",
                "id": "7",
                "sender": "You",
                "timestamp": "Wednesday 2:01pm"
            },
            {
                "content": "No ανβ3 integrin antagonists are yet approved. However, they are being investigated for the treatment of:\n* sickle cell disease vaso-occlusion\n* tumor angiogenesis\n* tumor-induced bone resorption\n* herpes simplex and hantavirus viral invasion\n* disruption of glomerular barrier function\n* dermal and hepatic fibrosis\n* acute myelogenous leukemia\n* postcardiac transplant coronary vasculopathy\n* bone resorption by multiple myeloma plasma cells\n* supravalvular aortic stenosis associated with Williams syndrome\n* Crohn’s disease strictures\n* t-cell lymphoma\n ",
                "id": "8",
                "sender": {
                    "name": "Biosym Bot",
                    "username": "@biosymbolics"
                },
                "timestamp": "Wednesday 2:02pm"
            }
        ],
        "sender": {
            "name": "Biosym Bot",
            "username": "@biosymbolics"
        }
    }
}
